126069-70-3

Basic information

• Product Name: Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)- (9CI)
• Synonyms: 2-(trifluoroMethyl)-5H,6H,7H,8H-iMidazo[1,2-a]pyrazine;2-(TrifluoroMethyl)-5,6,7,8-tetrahydroiMidazo[1,2-a]pyrazine HCl;IMidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoroMethyl)-;2-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine 2HCl;8-METHYL-2-(TRIFLUOROMETHYL)IMIDAZO[1,2-A]PYRAZINE;Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)- (9CI);2-(TRIFLUOROMETHYL)-5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE;2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine hydrochloride
• CAS NO: 126069-70-3
• Molecular Formula: C₇H₈F₃N₃
• Molecular Weight: 191.1537296
• Product Categories: PIPERIDINE;CHIRAL CHEMICALS
• Mol File: 126069-70-3.mol

Chemical Properties

• Boiling Point: 312.986 °C at 760 mmHg
• Flash Point: 143.089 °C
• Appearance: /
• Density: 1.56
• Vapor Pressure: 0.000511mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.90±0.20(Predicted)
• CAS DataBase Reference: Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)- (9CI)(126069-70-3)
• EPA Substance Registry System: Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)- (9CI)(126069-70-3)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• RIDADR: UN 2811 6.1 / PGIII
• HazardClass: IRRITANT
• Hazardous Substances Data: 126069-70-3(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)(9CI) is used as a research compound for studying the synthesis and properties of fused heterocycle-linked triazole derivatives. Its unique structure allows for the exploration of new chemical reactions and the development of novel compounds with potential applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Imidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-2-(trifluoromethyl)(9CI) may be used as a starting material or intermediate in the synthesis of new drugs. Its specific structural features could be exploited to design and develop innovative therapeutic agents with improved pharmacological properties.
Used in Material Science:
The compound may also find applications in material science, where its unique structural characteristics could be utilized to create new materials with specific properties, such as enhanced stability, reactivity, or selectivity in various chemical processes.

InChI:InChI=1/C7H8F3N3/c8-7(9,10)5-4-13-2-1-11-3-6(13)12-5/h4,11H,1-3H2

Upstream product

• 109113-96-4 2-trifluoromethylimidazo<1,2-a>pyrazine 

Downstream Products

• 936482-53-0 C₂₇H₂₉F₆N₇O₂ 
• 676994-43-7 C₂₀H₁₆ClF₃N₆O₂ 
• 1253800-46-2 7-[(2,4-dichlorophenyl)carbonyl]-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine 
• 1253801-40-9 7-[(2-chloro-4-fluorophenyl)carbonyl]-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine 
• 1253800-45-1 7-{[2-chloro-3-(trifluoromethyl)phenyl]carbonyl}-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine 
• 1575607-72-5 (2R,3R)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]piperazine-7(8H)-yl)butan-2-ol 

Relevant articles and documents

BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility

Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4] triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.

5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2/s

DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful the treatment of HIV and AIDS.

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS

This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R' to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful ín the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).